Stocktoria
SUPERNUS PHARMACEUTICALS, INC. SUPN
SUPERNUS PHARMACEUTICALS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $719.0M | $661.8M | $607.5M | $667.2M | $579.8M | $520.4M | $392.8M | $408.9M | $302.2M | $215.0M |
| R&D expense | $106.2M | $108.8M | $91.6M | $74.6M | $90.5M | $76.0M | $69.1M | $89.2M | $49.6M | $42.8M |
| SG&A expense | $485.6M | $321.6M | $336.4M | $377.2M | $304.8M | $200.7M | $153.2M | $154.7M | $137.9M | $106.0M |
| Operating income | -$62.3M | $81.7M | -$5.3M | $46.1M | $86.0M | $173.7M | $148.6M | $144.4M | $99.5M | $54.2M |
| Interest expense | — | — | — | — | $19.7M | $19.4M | $18.2M | $13.8M | $134,000 | $543,000 |
| Income tax | -$10.5M | $24.0M | $1.5M | $32,000 | $19.8M | $41.7M | $34.4M | $29.2M | $43.3M | -$40.9M |
| Net income | -$38.5M | $73.9M | $1.3M | $60.7M | $53.4M | $127.0M | $113.1M | $111.0M | $57.3M | $91.2M |
| EPS (diluted) | $-0.68 | $1.32 | $0.02 | $1.04 | $0.98 | $2.36 | $2.10 | $2.05 | $1.08 | $1.76 |
| Operating cash flow | $47.3M | $172.0M | $111.1M | $116.8M | $127.1M | $138.4M | $143.1M | $129.0M | $114.6M | $66.8M |
| Free cash flow | $46.0M | $171.2M | $110.5M | $116.4M | — | $134.9M | $140.4M | $128.1M | $112.6M | $65.2M |
| Cash & equivalents | $128.4M | $69.3M | $75.1M | $93.1M | $203.4M | $288.6M | $181.4M | $192.2M | $100.3M | $66.4M |
| Inventory | $112.5M | $54.3M | $77.4M | $91.5M | $86.0M | $48.3M | $26.6M | $25.7M | $16.3M | $16.8M |
| Total assets | $1.5B | $1.4B | $1.3B | $1.7B | $1.7B | $1.5B | $1.2B | $977.8M | $424.5M | $309.6M |
| Total liabilities | $390.9M | $332.3M | $356.2M | $816.3M | $873.3M | $759.2M | $564.9M | $524.8M | $157.0M | $117.8M |
| Shareholders' equity | $1.1B | $1.0B | $921.5M | $886.2M | $815.9M | $744.9M | $595.4M | $453.0M | $267.5M | $191.8M |
Growth · year-over-year · Revenue CAGR 14.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +8.6% | +8.9% | -8.9% | +15.1% | +11.4% | +32.5% | -3.9% | +35.3% | +40.6% | +45.8% |
| Net income growth | -152.2% | +5512.8% | -97.8% | +13.6% | -57.9% | +12.3% | +1.9% | +93.8% | -37.2% | +554.2% |
| EPS growth | -151.5% | +6500.0% | -98.1% | +6.1% | -58.5% | +12.4% | +2.4% | +89.8% | -38.6% | +528.6% |
| Free cash flow growth | -73.1% | +54.9% | -5.1% | — | — | -3.9% | +9.6% | +13.8% | +72.7% | +101.1% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.